Abbott Laboratories (NYSE: ABT) is an American multinational medical devices and healthcare company headquartered in Abbott Park, Illinois. Founded in 1888 by Dr. Wallace Abbott, the company has grown to become one of the world's largest healthcare companies, with annual revenues exceeding $40 billion and a market capitalization of approximately $220 billion as of 2026[@abbott2024]. Abbott operates across multiple healthcare segments, including medical devices, diagnostics, nutrition, and established pharmaceuticals, making it one of the most diversified healthcare conglomerates globally.
Within the field of neurodegenerative disease treatment, Abbott has established itself as a leading player in neuromodulation, particularly through its Infinity Deep Brain Stimulation (DBS) System, which provides therapeutic intervention for patients with [Parkinson's Disease](/diseases/parkinsons-disease), [Essential Tremor](/diseases/essential-tremor), and other movement disorders. The company's neuromodulation portfolio represents a strategic focus area that leverages its broader medical device expertise in cardiovascular and pain management technologies.
| Attribute | Details |
|-----------|---------|
| Founded | 1888 |
| Headquarters | Abbott Park, Illinois, USA |
| Stock Symbol | NYSE: ABT |
| Market Cap | ~$220 billion (2026) |
| 2025 Revenue | ~$40 billion |
| R&D Investment | ~$7 billion annually |
| Employees | ~115,000 |
| CEO | Robert B. Ford |
Abbott Laboratories was founded in 1888 by Dr. Wallace Abbott, a physician and pharmacist who began producing precise, portable dosage forms of medicine under the name "Abbott Alkaloidal Company"[@abbott]. The company's original focus was on creating reliable, standardized pharmaceutical preparations for physicians and patients—a mission that established Abbott's reputation for scientific rigor and product quality.
Throughout the late 19th and early 20th centuries, Abbott grew through both organic expansion and strategic acquisitions. The company went public in 1924, becoming one of the earliest publicly traded pharmaceutical companies in the United States. By the mid-20th century, Abbott had established itself as a major pharmaceutical company with a diverse portfolio spanning prescription pharmaceuticals, nutritional products, and medical devices.
Abbott's entry into the medical device business began in the 1960s and 1970s, focusing initially on vascular products and implants. The company recognized early that the intersection of pharmaceuticals and medical devices represented a significant opportunity for growth and innovation in treating complex diseases.
The 2016 acquisition of St. Jude Medical for approximately $25 billion marked a transformative moment for Abbott's medical device portfolio[@abbott2016]. This acquisition brought together two complementary medical technology companies, creating one of the world's largest medical device businesses. The St. Jude Medical acquisition specifically expanded Abbott's presence in cardiovascular devices, neuromodulation technologies, and diabetes management—each representing substantial growth markets.
The St. Jude Medical acquisition proved particularly significant for Abbott's neuromodulation business. Prior to the acquisition, St. Jude Medical had developed the Infinity DBS System, which represented a next-generation approach to deep brain stimulation therapy. The acquisition not only brought this technology into Abbott's product portfolio but also provided the scale and resources to accelerate its development and global commercialization.
Integration of the two companies' neuromodulation businesses created synergies in research and development, manufacturing, and global distribution. Abbott's existing infrastructure enabled faster regulatory approvals and market access for the Infinity DBS System, while the combined R&D capabilities accelerated the development of next-generation technologies including directional leads and closed-loop stimulation systems.
Abbott's neuromodulation division represents one of the company's fastest-growing business segments, focusing on therapeutic solutions for movement disorders, chronic pain, and emerging applications in other neurological conditions.
The Infinity DBS System is Abbott's flagship product for the treatment of movement disorders, particularly [Parkinson's Disease](/diseases/parkinsons-disease) and [Essential Tremor](/diseases/essential-tremor)[@odonovan2012]. Introduced following the St. Jude Medical acquisition, the Infinity system represents a significant advancement in DBS technology, featuring the smallest implantable pulse generator (IPG) available and advanced directional lead technology.
Key Technical Specifications:
| Feature | Specification |
|---------|---------------|
| IPG Dimensions | 38 mm length × 6 mm thickness |
| Battery Life | Up to 5 years (recharge-free option available) |
| Lead Configuration | 8-contact directional leads |
| MRI Compatibility | Full-body MRI conditional |
| Programming | Bluetooth-enabled patient controller |
The system's miniaturized IPG represents a significant patient benefit, as the smaller device is more comfortable for patients and requires less invasive surgical implantation procedures. This is particularly important for elderly patients who may have anatomical considerations that limit the size of implantable devices.
Directional Lead Technology:
The Infinity system's directional leads represent one of its most significant technological advances[@vezina2017][@wenger2019]. Unlike traditional omnidirectional leads that stimulate in all directions, directional leads allow clinicians to precisely direct electrical stimulation toward specific brain structures while minimizing stimulation of adjacent areas that may cause side effects.
This directional capability is particularly important for:
Abbott's spinal cord stimulation (SCS) systems provide therapeutic pain management through electrical modulation of spinal cord pain pathways. The Proclaim Elite and Proclaim XR systems represent Abbott's offerings in this space, featuring:
Abbott's NeuroSphere platform represents a digital health integration enabling remote patient monitoring and programming capabilities. This connected ecosystem allows healthcare providers to:
Deep brain stimulation works by delivering electrical signals to specific brain regions involved in movement control. In Parkinson's disease, the primary targets are the subthalamic nucleus (STN) and the globus pallidus internus (GPi)—structures that become overactive due to dopaminergic neuron loss[@okun2014][@benabid2009].
The electrical stimulation modulates abnormal neural firing patterns, effectively "replacing" the dysfunctional dopaminergic signaling that characterizes Parkinson's disease. This allows for:
Abbott's Infinity DBS system is FDA-approved for the treatment of [Parkinson's Disease](/diseases/parkinsons-disease) in patients meeting specific clinical criteria[@stypsis2020]:
Primary Indications:
The efficacy of DBS for Parkinson's disease is supported by extensive clinical evidence spanning over two decades of research and thousands of patients treated worldwide[@deep2019][@kalia2013].
Motor Symptom Improvement:
Cognitive and Psychiatric Considerations:
While DBS provides substantial motor benefits, cognitive and psychiatric outcomes require careful consideration[@rektorova2019]. Depression, anxiety, and other mood changes can occur, and patients require careful screening and monitoring. The subthalamic nucleus target has been associated with more cognitive risk than GPi, while GPi stimulation may have fewer neuropsychiatric effects[@castrioto2013].
Abbott competes directly with two other major DBS system manufacturers in the global market:
| Company | System | Key Differentiators |
|---------|--------|---------------------|
| Medtronic | Activa RC/PC | First to market, largest installed base, sensing capabilities |
| Boston Scientific | Vercise Genus | Directional leads (Cartesia), specialized waveforms |
| Abbott | Infinity | Smallest IPG, directional leads, Bluetooth connectivity |
Each system offers distinct advantages:
While not directly related to neurodegenerative diseases, Abbott's spinal cord stimulation systems represent a significant portion of the company's neuromodulation business and share technological principles with DBS.
Abbott's SCS systems are FDA-approved for:
The Proclaim system offers multiple stimulation modalities:
Abbott is the third major player in the global DBS market, behind Medtronic and Boston Scientific. However, the company has gained significant market share since acquiring the Infinity system through:
The DBS market for movement disorders is projected to grow substantially over the coming decade, driven by:
Abbott continues to invest in next-generation neuromodulation technologies:
Developing systems that automatically adjust stimulation based on real-time neural feedback, potentially improving therapeutic outcomes while reducing side effects. This adaptive approach could optimize stimulation on a moment-to-moment basis, responding to changes in patient symptoms throughout the day.
Research into systems capable of stimulating multiple brain regions simultaneously, potentially enabling more comprehensive symptom management for patients with complex presentations.
Exploring novel stimulation parameters that may provide improved efficacy or reduced side effects compared to conventional stimulation paradigms.
Early-stage research into neural interfaces that could eventually enable more sophisticated interaction between implantable devices and neural tissue.
Abbott's neuromodulation products have received regulatory clearance in major markets including:
Abbott's neuromodulation business represents a significant and growing portion of the company's overall medical device segment. The business benefits from:
Abbott's strategic direction in neuromodulation includes:
The following diagram shows the key molecular relationships involving Abbott Laboratories discovered through SciDEX knowledge graph analysis: